Two-headed PROTAC: an effective new tool for targeted protein degradation.
作者信息
Cyrus Kedra, Wehenkel Marie, Choi Eun-Young, Swanson Hollie, Kim Kyung-Bo
机构信息
Department of Pharmaceutical Sciences University of Kentucky 789 South Limestone, Lexington, KY 40536-0596, USA.
Department of Molecular and Biomedical Pharmacology University of Kentucky 800 Rose Street, Lexington, KY 40536, USA
出版信息
Chembiochem. 2010 Jul 26;11(11):1531-4. doi: 10.1002/cbic.201000222.
Abstract
摘要
相似文献
1
Two-headed PROTAC: an effective new tool for targeted protein degradation.
Chembiochem. 2010 Jul 26;11(11):1531-4. doi: 10.1002/cbic.201000222.
2
The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination.
Theranostics. 2020 Aug 8;10(22):10141-10153. doi: 10.7150/thno.46985. eCollection 2020.
3
Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras.
Colloids Surf B Biointerfaces. 2020 Apr;188:110795. doi: 10.1016/j.colsurfb.2020.110795. Epub 2020 Jan 13.
4
MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53.
Cancer Res. 2019 Jan 1;79(1):251-262. doi: 10.1158/0008-5472.CAN-18-2918. Epub 2018 Nov 1.
5
The application of ubiquitin ligases in the PROTAC drug design.
Acta Biochim Biophys Sin (Shanghai). 2020 Jul 10;52(7):776-790. doi: 10.1093/abbs/gmaa053.
6
Roche backs Aileron's stapled peptides.
Nat Biotechnol. 2010 Oct;28(10):992-3. doi: 10.1038/nbt1010-992c.
7
Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
J Med Chem. 2019 Feb 14;62(3):1420-1442. doi: 10.1021/acs.jmedchem.8b01572. Epub 2019 Jan 18.
8
A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells.
Front Immunol. 2023 Oct 2;14:1237964. doi: 10.3389/fimmu.2023.1237964. eCollection 2023.
9
PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy.
Front Pharmacol. 2021 May 7;12:692574. doi: 10.3389/fphar.2021.692574. eCollection 2021.
10
Target-directed enediynes: designed estramycins.
J Org Chem. 2001 Jun 1;66(11):3688-95. doi: 10.1021/jo0055842.
引用本文的文献
1
Unraveling the secrets of novel PROTACs to improve degradation efficacy.
Mol Divers. 2025 Jul 5. doi: 10.1007/s11030-025-11273-9.
2
Targeting the Undruggable: Recent Progress in PROTAC-Induced Transcription Factor Degradation.
Cancers (Basel). 2025 Jun 3;17(11):1871. doi: 10.3390/cancers17111871.
3
Development of PROTACs targeting estrogen receptor: an emerging technique for combating endocrine resistance.
RSC Med Chem. 2024 Dec 30. doi: 10.1039/d4md00961d.
4
Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics.
Chem Rev. 2025 Feb 26;125(4):2120-2183. doi: 10.1021/acs.chemrev.4c00595. Epub 2025 Jan 17.
5
New opportunities to overcome T cell dysfunction: the role of transcription factors and how to target them.
Trends Biochem Sci. 2024 Nov;49(11):1014-1029. doi: 10.1016/j.tibs.2024.08.002. Epub 2024 Sep 13.
6
Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies.
Acta Pharm Sin B. 2024 Feb;14(2):533-578. doi: 10.1016/j.apsb.2023.09.003. Epub 2023 Sep 12.
7
Targeted Protein Degradation: Clinical Advances in the Field of Oncology.
Int J Mol Sci. 2022 Dec 6;23(23):15440. doi: 10.3390/ijms232315440.
8
Direct targeting of TDP-43, from small molecules to biologics: the therapeutic landscape.
RSC Chem Biol. 2021 Jun 21;2(4):1158-1166. doi: 10.1039/d1cb00110h. eCollection 2021 Aug 5.
9
Sensitive manipulation of CAR T cell activity using a chimeric endocytosing receptor.
J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-000756.
10
Computer-Aided Ligand Discovery for Estrogen Receptor Alpha.
Int J Mol Sci. 2020 Jun 12;21(12):4193. doi: 10.3390/ijms21124193.
本文引用的文献
1
Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins.
J Am Chem Soc. 2010 Apr 28;132(16):5820-6. doi: 10.1021/ja100691p.
2
Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer.
Oncogene. 2008 Dec 4;27(57):7201-11. doi: 10.1038/onc.2008.320. Epub 2008 Sep 15.
3
Development of an aryl hydrocarbon receptor antagonist using the proteolysis-targeting chimeric molecules approach: a potential tool for chemoprevention.
Mol Pharmacol. 2008 Apr;73(4):1064-71. doi: 10.1124/mol.107.040840. Epub 2008 Jan 4.
4
Targeted degradation of the aryl hydrocarbon receptor by the PROTAC approach: a useful chemical genetic tool.
Chembiochem. 2007 Nov 23;8(17):2058-62. doi: 10.1002/cbic.200700438.
5
Targeted degradation of proteins by small molecules: a novel tool for functional proteomics.
Comb Chem High Throughput Screen. 2004 Nov;7(7):689-97. doi: 10.2174/1386207043328364.
6
Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain.
Science. 2004 Oct 1;306(5693):117-20. doi: 10.1126/science.1100946.
7
Chemical genetic control of protein levels: selective in vivo targeted degradation.
J Am Chem Soc. 2004 Mar 31;126(12):3748-54. doi: 10.1021/ja039025z.
8
Degradation of target protein in living cells by small-molecule proteolysis inducer.
Bioorg Med Chem Lett. 2004 Feb 9;14(3):645-8. doi: 10.1016/j.bmcl.2003.11.042.
9
Flavonoids as aryl hydrocarbon receptor agonists/antagonists: effects of structure and cell context.
Environ Health Perspect. 2003 Dec;111(16):1877-82. doi: 10.1289/ehp.6322.
10
Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation.
Mol Cell Proteomics. 2003 Dec;2(12):1350-8. doi: 10.1074/mcp.T300009-MCP200. Epub 2003 Oct 2.
Zotero 插件